STOCK TITAN

Agilent Joins the National Institute for Innovation in Manufacturing to Advance Biomanufacturing

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary

Agilent Technologies Inc. (NYSE: A) has joined the National Institute for Innovation in Manufacturing to Advance Biomanufacturing (NIIMBL), reinforcing its commitment to biopharmaceutical innovation. This partnership aims to enhance continuous manufacturing solutions, improve supply chain logistics, and increase accessibility to biotherapeutics. CEO Mike McMullen emphasized the growing importance of innovative measurement tools for delivering life-saving drugs. Agilent's advanced technologies, such as online HPLC sampling and real-time sensors, will play a vital role in shaping future bioprocess development.

Positive
  • Agilent's membership in NIIMBL highlights its dedication to biomanufacturing innovation.
  • Focus on continuous manufacturing can improve supply chain logistics and patient access.
  • Agilent offers advanced technologies that address critical needs in biopharmaceuticals.
Negative
  • None.

Support for biologics manufacturability and Industry 4.0 initiatives

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) announced that it has joined the National Institute for Innovation in Manufacturing to Advance Biomanufacturing (NIIMBL). Membership in NIIMBL demonstrates Agilent’s commitment to supporting biopharma and biotherapeutics customer challenges through partnership and innovation using tools and workflows.

The biomanufacturing industry is increasingly interested in continuous manufacturing solutions that can reduce the manufacturing footprint and improve supply chain logistics and biotherapeutic access by enabling manufacturing to move closer to patients, especially in underserved areas. The NIIMBL mission is to accelerate biopharmaceutical innovation, support the development of standards that enable more efficient and rapid manufacturing capabilities, and educate and train a world-leading biopharmaceutical manufacturing workforce, which will fundamentally advance U.S. competitiveness in the industry.

“Agilent has long played a key role in providing trusted answers for the analytical needs of the biopharmaceutical industry,” said Agilent CEO Mike McMullen. “The prominence of biopharmaceuticals coupled with the advent of precision cell and gene biotherapeutics has further spurred the need for innovative measurement tools to help deliver life-saving drugs and diagnostics to patients.”

Agilent’s online HPLC sampling portfolio, cellular imaging, and real-time sensor technologies exemplify how the company can help address current and emerging needs. Additionally, Agilent’s NIIMBL membership will allow us to work closely with all continuum partners to help shape the future of innovation and standards used in bioprocess development and biomanufacturing.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.32 billion in fiscal 2021 and employs 17,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

Naomi Goumillout

Agilent Technologies

+1.781.266.2819

naomi.goumillout@agilent.com

Source: Agilent Technologies Inc.

FAQ

What is Agilent Technologies' recent partnership in biomanufacturing?

Agilent has joined the National Institute for Innovation in Manufacturing to Advance Biomanufacturing (NIIMBL) to support biopharmaceutical innovation.

How does Agilent's membership in NIIMBL benefit the biomanufacturing industry?

The membership enables Agilent to collaborate on developing standards and innovative solutions in biopharmaceutical manufacturing.

What technologies is Agilent using to support biopharmaceutical manufacturing?

Agilent utilizes online HPLC sampling, cellular imaging, and real-time sensor technologies.

What was Agilent's revenue in fiscal 2021?

Agilent Technologies generated revenue of $6.32 billion in fiscal 2021.

Agilent Technologies Inc.

NYSE:A

A Rankings

A Latest News

A Stock Data

38.48B
286.42M
0.28%
91.26%
1.2%
Diagnostics & Research
Laboratory Analytical Instruments
Link
United States of America
SANTA CLARA